AGAVE BIOSYSTEMS INC. — Department of Defense SBIR Phase II: Recent studies have suggested the potential of improved malarial vaccines by use of the vi
AGAVE BIOSYSTEMS INC. — SBIR Phase II award from Department of Defense.
- Amount
- $629,510
- Agency
- Department of Defense · Army
- Program / Phase
- SBIR · Phase II
- Solicitation
- 2009.2
- NAICS
- —
- Place of performance
- NY
- Period
- 2011-08-01
Description
Recent studies have suggested the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems is creating a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.In the Phase I, Agave BioSystems successfully demonstrated proof-of concept for this novel platform.